NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.
Chronic active Epstein–Barr virus infection
Hematopoietic stem cell transplantation
Post-transplant lymphoproliferative disorder
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
06
09
2021
accepted:
03
12
2021
revised:
03
12
2021
pubmed:
11
1
2022
medline:
2
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Chronic active Epstein-Barr virus infection (CAEBV) is a systemic T- or NK-lymphoproliferative disorder (LPD) caused by EBV. Allogenic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for CAEBV, but relapse sometimes occurs. Relapse is generally attributed to proliferation of recipient-derived CAEBV cells. We herein report a case of donor-derived CAEBV-like NK-cell post-transplant lymphoproliferative disease (PTLD) in a 41-year-old female after the first allogenic HSCT for CAEBV from an HLA-matched sibling donor. A second HSCT from an HLA-matched unrelated donor successfully controlled the disease, but EBV infection of cells derived from the second donor continued to be detected. Although the mechanisms underlying CAEBV and CAEBV-like NK-cell PTLD have not yet been elucidated in detail, the findings of the present case imply that host genetic factors, including familial factors, may be important in disease development.
Identifiants
pubmed: 35001347
doi: 10.1007/s12185-021-03271-y
pii: 10.1007/s12185-021-03271-y
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-599Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Epstein MA, Achong BG, Barr YM. Virus particle in cultured lymphocytes from Burkitt’s lymphoma. Lancet. 1964;1(7335):702–3.
doi: 10.1016/S0140-6736(64)91524-7
Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395–404.
doi: 10.1016/S1074-7613(00)80622-6
Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet. 1978;2(8083):231–4.
doi: 10.1016/S0140-6736(78)91744-0
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
doi: 10.1182/blood-2016-01-643569
Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918–26.
doi: 10.1182/bloodadvances.2020001451
Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18.
doi: 10.1007/s12185-017-2192-6
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–49.
doi: 10.1182/blood-2010-11-316745
Shi M, Nguyen P, Timm MM, Otteson GE, Horna P, Olteanu H, et al. Cytoplasmic expression of CD3ε heterodimers by flow cytometry rapidly distinguishes between mature T-cell and natural killer-cell neoplasms. Am J Clin Pathol. 2020;154(5):683–91.
doi: 10.1093/ajcp/aqaa086
Arai A, Imadome K, Wang L, Wu N, Kurosu T, Wake A, et al. Recurrence of chronic active Epstein-Barr virus infection from donor cells after achieving complete response through allogeneic bone marrow transplantation. Intern Med. 2012;51(7):777–82.
doi: 10.2169/internalmedicine.51.6769
Yui S, Yamaguchi H, Imadome K, Arai A, Takahashi M, Ohashi R, et al. Epstein-Barr Virus-positive T-cell lymphoproliferative disease following umbilical cord blood transplantation for acute myeloid leukemia. J Nippon Med Sch. 2016;83(1):35–42.
doi: 10.1272/jnms.83.35
Iemura T, Kondo T, Hishizawa M, Yamashita K, Kimura H, Takaori-Kondo A. NK-cell post-transplant lymphoproliferative disease with chronic active Epstein-Barr virus infection-like clinical findings. Int J Infect Dis. 2019;88:31–3.
doi: 10.1016/j.ijid.2019.07.039
Sugaya N, Kimura H, Hara S, Hoshino Y, Kojima S, Morishima T, et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis. 2004;190(5):985–8.
doi: 10.1086/423285
Shibayama H, Imadome KI, Onozawa E, Tsuzura A, Miura O, Koyama T, et al. Virus-specific cytotoxic T cells in chronic active Epstein-Barr virus infection. Rinsho Ketsueki. 2017;58(6):583–8.
pubmed: 28679986
Sawada A, Inoue M. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders. Front Pediatr. 2018;6:334.
doi: 10.3389/fped.2018.00334
Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404–13.
doi: 10.1038/s41564-018-0334-0